One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Histological Scores in Inflammatory Bowel Disease: A New Kid in the Block
Mathurin Fumery, Denis Chatelain
doi : 10.1093/ecco-jcc/jjab083
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1603–1604
ECCO Topical Review: Refractory Inflammatory Bowel Disease
Tim Raine, Bram Verstockt, Uri Kopylov, Konstantinos Karmiris, Rimma Goldberg, Raja Atreya, Johan Burisch, John Burke, Pierre Ellul, Charlotte Hedin, Stefan D Holubar, Konstantinos Katsanos, Triana Lobaton, Carsten Schmidt, Garret Cullen
doi : 10.1093/ecco-jcc/jjab112
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1605–1620
Inflammatory bowel disease is a chronic disease with variable degrees of extent, severity, and activity. A proportion of patients will have disease that is refractory to licensed therapies, resulting in significant impairment in quality of life. The treatment of these patients involves a systematic approach by the entire multidisciplinary team, with particular consideration given to medical options including unlicensed therapies, surgical interventions, and dietetic and psychological support. The purpose of this review is to guide clinicians through this process and provide an accurate summary of the available evidence for different strategies.
Validation of the ‘Inflammatory Bowel Disease—Distribution, Chronicity, Activity [IBD-DCA] Score’ for Ulcerative Colitis and Crohn´s Disease
Corinna Lang-Schwarz, Miriam Angeloni, Abbas Agaimy, Raja Atreya, Christoph Becker, Theresa Dregelies, Silvio Danese, Jean-François Fléjou, Nikolaus Gaßler, Heike I Grabsch, Arndt Hartmann, Kate?ina Kamarádová, Anja A Kühl, Gregory Y Lauwers, Alessandro Lugli, Iris Nagtegaal, Markus F Neurath, Georg Oberhuber, Laurent Peyrin-Biroulet, Timo Rath, Robert Riddell, Carlos A Rubio, Kieran Sheahan, Britta Siegmund, Herbert Tilg, Vincenzo Villanacci, Maria Westerhoff, Fulvia Ferrazzi, Michael Vieth
doi : 10.1093/ecco-jcc/jjab055
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1621–1630
Histological scoring plays a key role in the assessment of disease activity in ulcerative colitis [UC] and is also important in Crohn´s disease [CD]. Currently, there is no common scoring available for UC and CD. We aimed to validate the Inflammatory Bowel Disease [IBD]—Distribution [D], Chronicity [C], Activity [A] score [IBD-DCA score] for histological disease activity assessment in IBD.
Histological Disease Activity Measured by the Nancy Index Is Associated with Long-term Outcomes in Patients with Ulcerative Colitis
Ferdinando D’Amico, Lucas Guillo, Cedric Baumann, Silvio Danese, Laurent Peyrin-Biroulet
doi : 10.1093/ecco-jcc/jjab063
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1631–1640
Histological healing might be the ultimate therapeutic goal in ulcerative colitis [UC]. Our aim was to investigate the association between histological disease activity as measured by a validated index and long-term outcomes in patients with UC.
‘These Discussions Aren’t Happening’: Experiences of People Living with Inflammatory Bowel Disease and Talking About Sexual Well-being with Health Care Professionals
Simona Fourie, Christine Norton, Debra Jackson, Wladyslawa Czuber-Dochan
doi : 10.1093/ecco-jcc/jjab043
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1641–1648
Inflammatory bowel disease [IBD] affects all aspects of life, yet little is known about the impact of the condition on intimacy and sexuality and if such concerns should be discussed with health care professionals. This hermeneutical phenomenological study aimed to explore the experiences of people living with inflammatory bowel disease and discussing their sexuality concerns with health care professionals.
Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn’s Disease: A Post-hoc Analysis
Neeraj Narula, Emily C L Wong, Parambir S Dulai, John K Marshall, Jean-Frederic Colombel, Walter Reinisch
doi : 10.1093/ecco-jcc/jjab045
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1649–1657
There is paucity of evidence on the reversibility of Crohn’s disease [CD]-related strictures treated with therapies. We aimed to describe the clinical and endoscopic outcomes of CD patients with non-passable strictures.
Ethnic Differences in the Smoking-related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Daniele Piovani, Claudia Pansieri, Soumya R R Kotha, Amanda C Piazza, Celia-Louise Comberg, Laurent Peyrin-Biroulet, Silvio Danese, Stefanos Bonovas
doi : 10.1093/ecco-jcc/jjab047
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1658–1678
The association between smoking and inflammatory bowel disease [IBD] relies on old meta-analyses including exclusively non-Jewish White populations. Uncertainty persists regarding the role of smoking in other ethnicities.
Inflammatory Bowel Disease in Patients with Congenital Chloride Diarrhoea
Lorenzo Norsa, Roberto Berni Canani, Remi Duclaux-Loras, Emeline Bequet, Jutta Köglmeier, Richard K Russell, Holm H Uhlig, Simon Travis, Jennifer Hollis, Sibylle Koletzko, Giusi Grimaldi, Giuseppe Castaldo, Astor Rodrigues, Jaques Deflandre, Lukasz Dembinski, Neil Shah, Peter Heinz-Erian, Andreas Janecke, Saara Leskinen, Satu Wedenoja, Ritva Koskela, Alain Lachaux, Kaija-Leena Kolho, Frank M Ruemmele on behalf of the GENIUS (GENetically determined ImmUne-mediated EnteropathieS) ESPGHAN working group and COLORS in IBD study (COLitis of early Onset - Rare diseaseS withIN IBD disease phenotypes) consortium
doi : 10.1093/ecco-jcc/jjab056
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1679–1685
Congenital chloride diarrhoea [CLD] is a rare autosomal recessive disease caused by mutations in the solute family carrier 26 member 3 [SLC26A3] gene. Patients suffer from life-long watery diarrhoea and chloride loss. Inflammatory bowel disease [IBD] has been reported in individual patients with CLD and in scl26a3-deficient mice.
Perianal Fistula-Associated Carcinoma in Crohn’s Disease: A Multicentre Retrospective Case Control Study
Chiara Palmieri, Gerhard Müller, Anton J Kroesen, Christian Galata, Andreas D Rink, Julia Morgenstern, Wolfgang Kruis
doi : 10.1093/ecco-jcc/jjab057
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1686–1693
Carcinoma associated with perianal fistula in Crohn’s disease is a pending threat for patients. This study aimed to improve understanding and facilitate development of diagnostic and therapeutic strategies.
Vedolizumab and Anti-Tumour Necrosis Factor ? Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
Brian Bressler, Andres Yarur, Mark S Silverberg, Marielle Bassel, Emanuelle Bellaguarda, Chris Fourment, Anthie Gatopoulou, Pantelis Karatzas, Uri Kopylov, George Michalopoulos, Spyridon Michopoulos, Udayakumar Navaneethan, David T Rubin, Jesse Siffledeen, Andrew Singh, Konstantinos Soufleris, Dara Stein, Dirk Demuth, Gerassimos J Mantzaris
doi : 10.1093/ecco-jcc/jjab058
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1694–1706
This study aimed to compare real-world clinical effectiveness and safety of vedolizumab, an ?4?7-integrin inhibitor, and anti-tumour necrosis factor-? [anti-TNF?] agents in biologic-naïve ulcerative colitis [UC] and Crohn’s disease [CD] patients.
Dose optimisation for Loss of Response to Vedolizumab— Pharmacokinetics and Immune Mechanisms
Bella Ungar, Karin Malickova, Jurij Hanžel, Muhammad Abu Arisha, Stephane Paul, Catia Rocha, Zohar Ben Shatach, Chaya Mushka Abitbol, Ola Haj Natour, Limor Selinger, Miri Yavzori, Ella Fudim, Orit Picard, Irit Shoval, Rami Eliakim, Uri Kopylov, Fernando Magro, Xavier Roblin, Yehuda Chowers, David Drobne, Milan Lukas, Shomron Ben Horin
doi : 10.1093/ecco-jcc/jjab067
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1707–1719
Real life data regarding pharmacokinetics of vedolizumab in patients needing dose optimisation are scarce. We set to examine whether pre-optimisation vedolizumab levels associate with therapy outcomes and which mechanisms explain the associations.
Overexpression of Vitamin D Receptor in Intestinal Epithelia Protects Against Colitis via Upregulating Tight Junction Protein Claudin 15
Ishita Chatterjee, Yongguo Zhang, Jilei Zhang, Rong Lu, Yinglin Xia, Jun Sun
doi : 10.1093/ecco-jcc/jjab044
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1720–1736
Dysfunction of the vitamin D receptor [VDR] contributes to the aetiology of IBD by regulating autophagy, immune response, and mucosal permeability. VDR directly controls the paracellular tight junction protein Claudin-2. Claudin-2 and Claudin-15 are unique in maintaining paracellular permeability. Interestingly, claudin-15 mRNA was downregulated in patients with ulcerative colitis. However, the exact mechanism of Claudin-15 regulation in colitis is still unknown. Here, we investigated the protective role of VDR against intestinal inflammation via upregulating Claudin-15.
Potential Role of Epithelial Endoplasmic Reticulum Stress and Anterior Gradient Protein 2 Homologue in Crohn’s Disease Fibrosis
Sophie Vieujean, Shurong Hu, Emeline Bequet, Catherine Salee, Charlotte Massot, Noëlla Bletard, Nicolas Pierre, Florence Quesada Calvo, Dominique Baiwir, Gabriel Mazzucchelli, Edwin De Pauw, Carla Coimbra Marques, Philippe Delvenne, Florian Rieder, Edouard Louis, Marie-Alice Meuwis
doi : 10.1093/ecco-jcc/jjab061
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1737–1750
Intestinal fibrosis is a common complication of Crohn’s disease [CD]. It is characterised by an accumulation of fibroblasts differentiating into myofibroblasts secreting excessive extracellular matrix. The potential role of the intestinal epithelium in this fibrotic process remains poorly defined.
Matrix Metalloproteinase MMP-12 Promotes Macrophage Transmigration Across Intestinal Epithelial Tight Junctions and Increases Severity of Experimental Colitis
Meghali Nighot, Ashwinkumar Subramenium Ganapathy, Kushal Saha, Eric Suchanec, Eliseo F Castillo, Alyssa Gregory, Steven Shapiro, Thomas Ma, Prashant Nighot
doi : 10.1093/ecco-jcc/jjab064
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1751–1765
Matrix metalloproteinases [MMPs] play an important role in extracellular matrix regulation during cell growth and wound healing. Increased expression of MMP-12 [human macrophage elastase] has been reported in inflammatory bowel disease [IBD] which is characterised by the loss of epithelial tight junction [TJ] barrier function and an excessive inflammatory response. The aim of this study was to investigate the role of MMP-12 in intestinal TJ barrier function and inflammation.
Colonic Strictures in Inflammatory Bowel Disease: Epidemiology, Complications, and Management
Mathurin Fumery, Clara Yzet, Denis Chatelain, Thierry Yzet, Franck Brazier, Jean-Philippe LeMouel, David Laharie, Charles Sabbagh
doi : 10.1093/ecco-jcc/jjab068
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1766–1773
The management of colorectal stricture complicating inflammatory bowel disease [IBD] remains a challenging condition. Stricture raises concern about neoplastic complications, which cannot be fully ruled out by negative endoscopic biopsies. Also, impassable strictures restrict the endoscopic monitoring of upstream disease activity and dysplasia. Surgery remains the ‘gold standard’ treatment for colonic strictures but is associated with high morbidity. Over the past few decades, our therapeutic arsenal for IBD has been reinforced by biologics and therapeutic endoscopy. Few studies have focused on colonic strictures, and so current therapeutic strategies are based on a low level of evidence and applied by analogy with the treatment of ileal strictures. With a view to facilitating the decision making process in clinical practice, we reviewed the literature on the epidemiology, natural history, and management of colonic strictures in IBD.
Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis
Alexander Clevewood Ng
doi : 10.1093/ecco-jcc/jjab062
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Page 1774
Response to ‘Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis’
Sailish Honap, Peter M Irving, Nicholas A Kennedy
doi : 10.1093/ecco-jcc/jjab080
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1775–1776
Anti-TNF Therapy Before Intestinal Surgery for Crohn’s Disease and the Risks of Postoperative Complications
Mattias Soop, Laura Hancock, Justin Davies
doi : 10.1093/ecco-jcc/jjab054
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Page 1777
At the Crossroads of Caution and Intervention: Anti-TNF Therapy Prior to Elective CD Surgery
Michel Adamina, Gionata Fiorino
doi : 10.1093/ecco-jcc/jjab092
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1778–1779
Gut–Brain Interactions in Patients with Inflammatory Bowel Disease and the Role of Hypnotherapy in Managing Symptoms
Johannah Ruddy, Tiffany Taft, Daniel Keszthelyi
doi : 10.1093/ecco-jcc/jjab053
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Pages 1780–1781
Holistic approach to IBD patients
Ehud Mekori-Domachevsky, Shomron Ben-Horin
doi : 10.1093/ecco-jcc/jjab059
Journal of Crohn's and Colitis, Volume 15, Issue 10, October 2021, Page 1782
